APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)

Gunter Von Minckwitz, Marion Jennifer Procter, Evandro De Azambuja, Dimitrios Zardavas, Adam Knott, Giuseppe Viale, Thomas M. Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark, Mark Benyunes, Istvan Lang, Christelle Levy, Denise A. Yardley, Jose Bines, Richard D. Gelber, Martine J. Piccart-Gebhart, Jose Baselga

German Breast Group (GBG), Neu-Isenburg, Germany
Frontier Science (Scotland) Ltd., Kingussie, United Kingdom
Institut Jules Bordet, Brussels, Belgium
Breast International Group, Brussels, Belgium
Roche Products, Ltd., Welwyn, United Kingdom
Department of Pathology, European Institute of Oncology and University of Milan, Milan, Italy
University Hospital Bern, Bern, Switzerland
Genentech, Inc., San Francisco, CA
National Institute of Oncology, Budapest, Hungary
Centre François Baclesse, Caen, France
Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN
National Cancer Institute, Rio de Janeiro, Brazil
Dana-Farber Cancer Institute, Boston, MA
Jules Bordet Institute, Brussels, Belgium
Memorial Sloan Kettering Cancer Center, New York, NY